CompletedPhase 2NCT00098774
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
Studying Non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- James Rubenstein, MD, PhDUniversity of California, San Francisco
- Intervention
- filgrastim(biological)
- Enrollment
- 47 enrolled
- Eligibility
- All sexes
- Timeline
- 2004 – 2014
Study locations (30)
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States
- CCOP - Christiana Care Health Services, Newark, Delaware, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
- Hematology Oncology Associates of the Quad Cities, Bettendorf, Iowa, United States
- Menorah Medical Center, Overland Park, Kansas, United States
- Saint Luke's Hospital - South, Overland Park, Kansas, United States
- Shawnee Mission Medical Center, Shawnee Mission, Kansas, United States
- Union Hospital Cancer Program at Union Hospital, Elkton MD, Maryland, United States
- Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
- Truman Medical Center - Hospital Hill, Kansas City, Missouri, United States
- Saint Luke's Cancer Institute at Saint Luke's Hospital, Kansas City, Missouri, United States
- St. Joseph Medical Center, Kansas City, Missouri, United States
- North Kansas City Hospital, Kansas City, Missouri, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00098774 on ClinicalTrials.govOther trials for Non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasUniversity of California, San Diego
- RECRUITINGNCT07313943PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGEIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT07283822Amping up With PemJAKSeda S. Tolu
- RECRUITINGNANCT06923397Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT06854003BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaChristine Ryan
- ACTIVE NOT RECRUITINGPHASE1NCT06622226A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin LymphomaOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06522932PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T TherapyMichael Randall
- RECRUITINGPHASE1NCT06420089CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)Vittoria Biotherapeutics